New York : A new pre-operative drug therapy to reduce antibodies in kidney patients may increase their chance for kidney transplantation and decrease the likelihood of organ rejection, says a study, reports IANS.
The new therapy was found to reduce antibodies with greater success than with traditional methods in a clinical trial spanning over three years. “This study is important because it has the potential to change the way we approach kidney transplantation,” said the study’s principal investigator, E Steve
Woodle from University of Cincinnati.
Antibodies are Y-shaped proteins which, in most instances, are good because they help fight infection, but people can also make antibodies that work against other humans, which is often a major barrier to transplantation.
Since 2008, the researchers have been on forefront of developing therapies that target plasma cells – the cells that make antibodies.
